Abstract: Provided herein are topical composition comprising tapinarof and combination compositions comprising a therapeutically effective dose of tapinarof and a therapeutically effective dose of at least one additional active agent, selected from at least one corticosteroid, calcipotriene, at least one JAK inhibitor and combinations thereof, and a carrier suitable for topical administration. The above compositions are useful for the treatment, prevention or alleviation of skin disorders selected from psoriasis and atopic dermatitis and exhibit synergistic or additive effects which allow reducing the doses of the active agents in the compositions.

Abstract: The present application is directed to stabilized core-shell microcapsules comprising a core of benzoyl peroxide (BPO) or all trans retinoic acid (ATRA) and a metal-oxide shell; and to pharmaceutical compositions and methods of use thereof.

Abstract: This invention is directed to a regimen administration of combination of minocycline and benzoyl peroxide and uses thereof for treating a skin disorder such as acne or rosacea.

Abstract: Disclosed are simple yet stable and effective compositions comprising from about 1% to about 5% by weight of the composition of a minocycline or mixtures thereof and pharmaceutically acceptable ingredients comprising from about 60% to about 99% by weight of the composition of at least one hydrophobic oil, and from about 5% to about 25% by weight of the composition of at least one fatty alcohol, wherein the at least one hydrophobic oil and the at least one fatty alcohol are sufficient to ensure the pharmaceutically acceptable assay stability of the minocycline in the composition under 3 months accelerated stability conditions at 40° C./75% RH. Also disclosed are methods of treatment of acne, rosacea and impetigo.

Abstract: The present application is directed to stabilized core-shell microcapsules comprising a core of benzoyl peroxide (BPO) or all trans retinoic acid (ATRA) and a metal-oxide shell; and to pharmaceutical compositions and methods of use thereof.

Abstract: The present application is directed to stabilized core-shell microcapsules comprising a core of benzoyl peroxide (BPO) or all trans retinoic acid (ATRA) and a metal-oxide shell; and to pharmaceutical compositions and methods of use thereof.

Abstract: The present application is directed to stabilized core-shell microcapsules comprising a core of benzoyl peroxide (BPO) or all trans retinoic acid (ATRA) and a metal-oxide shell; and to pharmaceutical compositions and methods of use thereof.